New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:08 EDTTSROTESARO and AnaptysBio collaborate on immuno-oncology antibody program
TESARO and AnaptysBio announced a strategic immuno-oncology collaboration under which AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody candidates from these programs are expected to enter clinical trials over the next 18 to 24 months. TESARO will pay an upfront license fee of $17M and provide funding of costs incurred by AnaptysBio related to the development programs. For each development program, AnaptysBio is eligible to receive milestone payments associated with certain U.S. and ex-U.S. regulatory submissions and approvals in multiple indications. AnaptysBio and TESARO will together complete preclinical development of the antibody candidates, with TESARO being solely responsible for all clinical development, manufacturing, regulatory and commercial activities.
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
11:15 EDTTSROTESARO participates in a conference call with Leerink
Analyst Fernandez holds a conference call with CEO Moulder and COO Hedley to discuss the upcoming launch dynamics for Varubi, data read-outs for Niraparib and the development plans for the company's immuno-oncology portfolio on October 15 at 1 pm.
October 1, 2015
07:31 EDTTSROLeerink to hold a roundtable
Subscribe for More Information
September 29, 2015
10:09 EDTTSROHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use